BPC-157 Vial | 10mg
£30.00
Sale price
£30.00
Regular price
Skip to product information
Administered every 1–3 days
BPC-157 Pen
Starting at £20 per vial with a
subscription plan
10mg BPC-157 research solution, precisely dosed and independently verified by Janoshik Analytical. Synthetic pentadecapeptide studied extensively in published laboratory research settings. For research purposes only.
Meet the BPC-157 Pen
-
Ready-to-use research solution
-
≥99% purity, third-party verified
-
Pharmaceutical grade research formulation
-
Free shipping on all UK orders
Pickup currently not available
BPC-157 | A synthetic pentadecapeptide studied in experimental and preclinical research for its potential role in supporting tissue regeneration, recovery pathways, gut integrity, and cellular repair mechanisms. Frequently explored in laboratory models focused on muscle, tendon, ligament, and digestive system recovery due to its regenerative and protective properties.*
Our compounds are manufactured by Homopeptides and every batch is independently analysed by Janoshik Analytical before reaching you. Janoshik are one of the most respected third-party testing laboratories in the peptide research space — their verification gives you confidence in every order.
This compound is supplied as a lyophilised powder and is intended for reconstitution prior to laboratory use. Store at 2–8°C in a refrigerator, protected from light, heat and moisture. Reconstitute only using an appropriate research-grade diluent immediately before use. Once reconstituted, stability will depend on the selected diluent and storage conditions. For laboratory and research purposes only.*
All orders are dispatched within 1–2 business days. Compounds are packaged with temperature-controlled materials to maintain integrity during transit. Free shipping on all UK orders.
Compounds built for
precision
years of published preclinical research investigating BPC-157's effects on tissue repair, angiogenesis, and gastrointestinal healing.*
Of tendon-focused BPC-157 studies reviewed reported improved healing outcomes versus controls.*
*Based on published peer-reviewed in-vitro research. For research purposes only.
. Phase II clinical development of PL 14736
(BPC-157) reported no significant toxicity or serious adverse events in inflammatory bowel disease patients. Sikiric P et al. "Stable Gastric Pentadecapeptide BPC 157." Curr Pharm Des. 2010;16(10):1224–1234.
